Endometriosis is a multifactorial disease with possible genetic predisposition and involvement of environmental factors in its pathogenesis. The genetic polymorphism of glutathione S-transferase M1 (GSTM1) gene, which codes for glutathione S-transferase 1, class µ foreign compound conjugating enzyme of phase II detoxification system, was studied by polymerase chain reaction from the blood spots in patients with different stages of endometriosis (n ⍧ 50) and in controls (n ⍧ 72) of French origin. A total of 86.0% of patients appeared to lack GSTM1 enzyme activity due to the presence of an extended deletion (GSTM1 0/0 genotype), compared with 45.8% in a control group (P < 0.0001), which was consistent with the frequency of GSTM1 deletion in French population. Moreover, the distribution of GSTM1-active genotypes was significantly different in patients and controls (P < 0.0001), as no patient with GSTM1A/B genotype, which is correlated with the highest activity of GSTM1 enzyme, has been found so far (18.1% in a control group). The unusually high frequency of homozygotes for the GSTM1 gene deletion among patients with endometriosis suggests a possible contribution of environmental toxins in the pathogenesis of this disease due to the absence or low activity of GSTM1 enzyme.
Introduction
Endometriosis is a widespread disease with a frequency of 10% in the general Caucasian population. It contributes significantly to infertility problems in the industrialized world (Berger et al., 1993) .
The aetiology and pathogenesis of endometriosis are still unclear. The results of epidemiological family studies (Simpson et al., 1980; Moen et al., 1993) and environmental investigations mean endometriosis can be considered as a multifactorial disease with a possible genetic predisposition (Kennedy et al., 1996) and with the involvement of environmental toxins, specially dioxins and polychlorodiphenyl compounds (PCBs), in its pathogenesis (Gibbons, 1993; Rier et al., 1993) .
We have started a series of investigations devoted to the detoxification system genes, especially the glutathione Stransferase M1 gene (GSTM1), and their impact in predisposition and development of endometriosis. The first results of these studies have recently been published (Baranov et al., 1996) .
The GSTM1 gene belongs to the GST gene family formerly termed µ or GST1 (Mannevrik et al., 1992) . Its protein product, glutathione S-transferase 1, class µ, corresponds with the group of phase II foreign compound-metabolizing enzymes with especially high specificity for certain electrophilic chemicals, such as trans-stilbene oxide and carcinogenic metabolites of benzopyrene. It also functions as an intracellular drug-and hormone-binding protein (Chasseaud et al., 1979) . GSTM1 gene is expressed in various tissues such as liver, gut, lymphocytes, urothelium, mononuclear leukocytes (Seidegard et al., 1988; Liu et al., 1991) .
GSTM1 gene is assigned to chromosome 1p13 (Zhong et al., 1992) and is present in two active alleles: GSTM1*A, GSTM1*B and one null allele (GSTM1*0) (Brockmuller et al., 1994) . Their combination corresponds to GSTM1A/A or A/0; GSTM1B/B or B/0 and GSTM1A/B active genotypes and one non-active genotype, GSTM10/0, that does not have any mRNA or protein product due to an extended deletion (10 kb) (Seidegard et al., 1988) . This GSTM10/0 genotype is found in 40-50% in different populations (Groppi et al., 1991; Harada et al., 1992) and affects the detoxification processes of endogenous and exogenous compounds as well as the metabolism of drugs. It has already been shown that GSTM1-negative individuals are assumed to be at risk for lung and bladder cancer (Seidegard et al., 1990; Brockmuller et al., 1994) , which have been determined to be predominantly environmentally induced diseases (Vineis et al., 1991; Viscoli et al., 1993) .
The principal goal of the present study is to analyse the distribution of GSTM10/0-deficient and GSTM1-active genotypes in patients at different stages of endometriosis and a control group relative to age, smoking and other life history factors.
Materials and methods

Study design and inclusion criteria
Patients: Our hospital-based case control study was carried out between January 1996 and December 1996 in groups of patients with different stages of endometriosis and in controls of French origin in the Polyclinique, Center Hospitalier Université de Clermont-Ferrand, France. Only patients with clinically, endoscopically and histologically confirmed diagnoses were studied (Canis et al., 1995) . The control group included women of reproductive age without any malignant pathology, who were admitted to the hospital for voluntary abortion. The anamnestic data were obtained in a 10 min interview by the clinicians. For statistical analysis, information about smoking (current, regular or occasional; Periot, 1995), allergy (delayed or intermediated hypersensitivity and type of allergy; Bousquet et al., 1993) , chronic diseases and the history of previous pregnancies was scored as present/absent. Classification of endometriosis: Patients were staged according to the revised American Fertility Society (AFS, 1985) classification and classified into following groups: group 1 ϭ AFS stage I-II; group 2 ϭ AFS stages III-IV.
Statistical analysis
The minimum sample size was determined on the basis of our previous results (Baranov et al., 1996) and was estimated as 38 subjects for each diagnostic group (two-sided test, power (1-β): 90% significance level α: 5%). In total, 50 patients with endometriosis and 72 controls were analysed.
The BMDP4F program (Dixon et al., 1992) was used to calculate the Pearson χ 2 test of independence and, if the minimum expected frequency was too low, Fisher's exact test was applied. MantelHaenszel analysis (Mantel et al., 1959) were used to estimate the odds-ratio common to different levels and to test whether it was equal to one.
Collection of material and polymerase chain reaction analysis
Blood spots collected on filter paper from each patient were used directly for polymerase chain reaction (PCR) without prior DNA extraction, as described previously by Baranov et al. (1991) . The PCR analyses were carried out: (i) to distinguish between GSTM1-positive and GSTM1-negative subjects (internal standard-controlled PCR) and (ii) for precise allelic detection (nested PCR).
The GSTM1 deficiency was identified by internal standard-controlled PCR for the part of the 4th exon (result product 271 bp in GSTM1-active individuals) with oligoprimers G1 and G2 (5Ј-CTGCCCTACTTGATTGATGGG-3Ј; 5Ј-CTGGATTGTAGCAGAT-CATGC-3Ј) (Bruckmuller et al., 1994; Baranov et al., 1996) .
Co-amplification of a DNA fragment (93 bp) encompassing the ∆F508 mutation in exon 10 of the cystic fibrosis (CFTR) gene with standard oligoprimers (Baranov et al., 1991) was used as an internal control. External positive and negative controls from GSTM1-active and GSTM1-negative individuals were also included. PCR reaction was carried out as described (Baranov et al., 1996) . Briefly, a small fragment of the blood spot (~1 mm 2 ) was plunged into 25 µl of amplification mixture [2.5 µl of 10 mM dNTP, 2.5 µl of 10ϫ PCR buffer (GibcoBRL; Life Technologies SARL, Cedex, France), 1.5 µl of 50 mM MgCl 2 (GibcoBRL), 1 µl of each primer (50 mM) 2 IU Taq DNA polymerase (GibcoBRL), H 2 O up to 25 µl] and was overlaid with one drop of mineral oil. The following PCR parameters were used: 7 min of initial denaturation at 94°C; 35 cycles: 94°C 40 s, 56°C 1 min, 72°C 1 min; final extension 7 min.
Nested PCR analysis for GSTM1 allelic confirmation was per-776 formed as described (Brockmuller et al., 1994) with slight modifications for the direct PCR procedure from the blood spots with the following primers for the seventh exon. In the first reaction, the product was expected to be 1252 bp, with the outer primers: G6 5Ј-CTCAAAGCGGGAGATGAAAGTC-3Ј; G18 5Ј-ACCATATGC-AGCTGGGCATGA-3Ј [for 25 µl of amplification mixture: 2.5 µl of 10 mM dNTP, 2.5 µl of 10ϫ PCR buffer, 2.5 µl of 50 mM MgCl 2 , 1 µl of each primer (50 mM), 3 IU of Taq DNA polymerase, H 2 O up to 25 µl]; the PCR parameters were: 7 min of initial denaturation at 94°C; 35 cycles: 94°C 40 sec, 59°C 1 min, 72°C 2 min; final extension 7 min. The second step of nested procedure was performed immediately after the first one without prior electrophoretic analysis. The resulting product of the second reaction was 214 bp and the inner primers were: G7 5Ј-AGGCGTCCAAGCAG-3Ј and G9 5Ј-TAAAGCTCTACTCAGAGT-3Ј for detection of GSTM1*B allele and G8 5Ј-AGGCGTCCAAGCAC-3Ј with G9 for detection of GSTM1*A allele [for 25 µl of amplification mixture: 1 µl of 10mM dNTP, 2.5 µl of 10ϫ PCR buffer, 2.5 µl of 50 mM MgCl 2 , 0.5 µl of each primer (50 mM), 2 IU of Taq DNA polymerase, 2 ml of the first step amplification mixture, H 2 O up to 25 µl]; the PCR parameters were: 5 min of initial denaturation at 94°C; 12 cycles: 94°C 40 sec, 55°C 1 min, 72°C 1.5 min; final extension 7 min). Nested PCR procedure was performed independently from detection of GSTM1 deficiency, however, the results of the internal standard-controlled PCR did not differ from the results of nested PCR and all individuals positive for the first PCR test were also positive for the second one. The electrophoresis was carried out in 7% polyacrylamide gel at 200 V 90 min stained with ethidium bromide.
A correlation between GSTM1-deficient genotype and GSTM1 enzyme activity has already been shown in other GSTM1 investigations (Brockmuller et al., 1994) and our previous studies (Baranov et al., 1996) , so it was not performed in the present work.
Results
The PCR methods used in our investigation enabled the distinction of GSTM1-active and GSTM1-deficient subjects (Figure 1 ) and confirmed the presence of active GSTM1 genotypes by nested PCR for precise allelic detection (Figure 2 ).
The results demonstrate that 86.0% of our 50 endometriosis patients had GSTM1 deficiency compared with 45.8% in the control group (Table I) . To date, no patient with a GSTM1A/ B genotype has been found. Distribution of GSTM1B/B or B/ 0 active genotypes was nearly equal in the patients and the controls (8.0 and 6.9% respectively), but the proportion of GSTM1A/A or A/0 genotypes was significantly higher in the controls: 29.2% compared with only 6.0% in patients.
The summarized statistical analysis showed a significant preponderance of GSTM10/0 genotype and reduction of GSTM1 active alleles in endometriosis patients compared with the control group (GSTM10/0, P Ͻ 0.0001; GSTM1-active genotype, P Ͻ 0.0019) (Table II) .
There was a difference in distribution of individuals in diagnostic groups depending on age (P Ͻ 0.001) and smoking (P Ͻ 0.0135) ( Table II) . The latter difference might be partly attributed to the age difference between controls and patients (patients mean age ϭ 35.8 years; controls mean ages ϭ 27.5 years). Taking this into account, a Mantel-Haenszel test was carried out to study the distribution of genetic and life history factors in patients and controls according to age (Table III) . 
Genetic factors
The difference in distribution of GSTM1 genotypes between patients and controls has been proved and appears to be highly significant (Mantel-Haenszel test: P ϭ 0.0001; 95% confidence limits: 0.04-0.32).
Life history factors
The difference was also confirmed for smoking (Mantel- Haenszel test: P ϭ 0.0212; 95% confidence limits: 1.07-7.19) and detected for pregnancy (Mantel-Haenszel test: P ϭ 0.0477; 95% confidence limits: 1.05-6.45; marginal statistical significance levels). However, the proportion of the second factor (previous pregnancies in anamnestic data) was equal in controls and patients (50.0 compared with 50.0%) ( Table I) .
No difference between patients and controls has been registered up to date according to the presence of allergy and chronic disease. Nevertheless, certain interaction between these two factors was found (P ϭ 0.0011).
Discussion
GSTM1-deficiency
Genotyping shows a statistically proved over-representation of GSTM10/0 homozygotes in our endometriosis patients compared with controls. These results are consistent with the proportion of GSTM1-negative individuals in endometriosis patients in Russia (81.0 compared with 38.8% in controls; P Ͻ 0.001); (Baranov et al., 1996) . The same phenomenon was also found in a Ukrainian population (76.7 against 53.5% in controls; P Ͻ 0.05; unpublished data). Absence of GSTM1A/ B active genotype in our patients might be taken as another argument for the involvement of GSTM1 deficiency in endometriosis and needs special attention.
The reduced frequency of GSTM1A/B genotype was demonstrated in patients with bladder cancer (Brockmuller et al., .6) Table I for definition of groups. *Significant (P value). NS ϭ non-significant. 1994) and with basal cell carcinoma (Heagerty et al., 1994) in individuals of German and English origin. However, in these studies the proportion of GSTM1A/B genotype was lower in controls for German females (3.3%) (Brockmuller et al., 1994) and 6.0% in subjects of English origin (Heagerty et al., 1994) , compared with 18.1% in our control group of French females. To our knowledge, only distribution of GSTM10/0 deletion, but not GSTM1-active genotypes has been studied in France (Groppi et al., 1991) . So, the high frequency of GSTM1A/B genotype in the French population should be considered with caution, due to the small number of studied subjects, and a definitive conclusion cannot be given. Nevertheless, the lack of this genotype is quite obvious in our patients. The under-representation of GSTM1A/0 or GSTM1A/A genotypes (6.0% in endometriosis patients compared with 29.2% in controls) found in the present study, has also been reported for bladder cancer patients (Brockmuller et al., 1994) . These results and previous GSTM1 studies of endometriosis suggest a possible impact of GSTM1 deficiency in the predisposition to this disease, most probably through the involvement of environmental toxins or their metabolites in its pathogenesis (Gibbons, 1993; Rier et al., 1993) .
Participation of other genetic factors has recently been 778 reported in the pathogenesis of endometriosis; e.g. (i) loss of heterozygosity (LOH), which may provoke tumour suppressor gene inactivation in endometriosis patients (Jiang et al., 1996) ; (ii) expression of human leukocyte antigen (HLA) class I and B7, which suggests that the growth of ectopic endometrial cells might be under genetic control (Semino et al., 1995) ; (iii) N314D mutation of galactose-1-phosphate uridyl transferase gene (GALT), which is associated with abnormalities of galactose metabolism and might cause canal forming defects of the Müllerian tract, cervical stenosis and vaginal agenesis (Cramer et al., 1996) . The last studies (Cramer et al., 1996) support the notion that endometriosis is connected with the mechanism of retrograde menstruation, which is developed due to canal forming defects. All these data prove that endometriosis is a multifactorial disease, where different factors with genetic basis may take place, therefore the combined approach in endometriosis studies is indispensable.
Cigarette smoking and other life history factors
There were differences between the groups studied in relation to smoking; the proportion of smokers in endometriosis patients was 24.0 compared with 52.8% in controls; this may be due to the age difference between the groups. According to epidemiological studies in France, the highest proportion of smokers (63.4%) is found in the 18-24 year old age group for females, but significantly decreases with age and appears to be 33.4% for females in the general French population (Grizeau et al., 1993) . Nevertheless, the number of smokers was higher in endometriosis patients of group 1 (I and II stages), than in patients of group 2 (stages III and IV) ( Table I) . Further investigation of this phenomenon is needed and study designs including registration of pack-years in each case, but the trend to protective effect of smoking cannot be excluded. Moreover, it was also demonstrated in previous endometriosis epidemiological studies (Matorras et al., 1995) .
The other life history factors, such as chronic pathology, allergy and previous pregnancies did not show significant influence on susceptibility to endometriosis to date. The marginal statistical significance levels for pregnancy may be explained by certain increase of this factor in anamnesis with age due to biological and social conditions.
Lack of detoxification and environmentally induced disease
The fact that a high percentage of GSTM10/0 homozygotes has also been found in patients with lung cancer, bladder cancer, cutaneous tumours and even chronic bronchitis (Baranova et al., 1997) , diseases which are regarded as being environmentally induced, needs special attention. The GSTM1 enzyme corresponds to the phase II detoxification process and it participates in detoxification by conjugation of the toxic substances with glutathione, which is activated during phase I of xenobiotic metabolism by cytochrome P-450 (CYP) (Raunio et al., 1995) . The lack of GSTM1 activity may be considered as a risk factor for the development of different environmentally associated diseases and might be considered as a convenient biomarker (Daly et al., 1994) . As has been shown in bladder cancer patients, GSTM1 deficiency is responsible for 17% of cases of this disease (Brockmuller et al., 1994) . The fact that subjects with the lack of GSTM1 activity may develop different types of pathology confirms the involvement of other, possibly genetic, factors in each particular disorder. The high proportion of GSTM1-deficient individuals among endometriosis patients might be interpreted as evidence of participation of environmental toxins in the pathogenesis of this disease. More studies are needed, including investigations of the phase I detoxification system, specially CYP1A1 and the other members of CYP-450 family, known as dioxin inducible genes (Nakachi et al., 1993; Vanden et al., 1993) , before any definitive conclusion could be drawn.
